Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells

Cellular Immunology

Volumn 221, Issue 2, 2003, Pages 81-88

  Sartorius, Rossella ^a   D'Apice, Luciana ^a   Barba, Pasquale ^b   Guardiola, John ^b   Santoni, Angela ^c   Velotti, Francesca ^d   De Berardinis, Piergiuseppe ^a  

^a INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TUSCIA   (Italy)

Author keywords

APC; CD3; CD56; IL 15; IL 2; Magnetic microbeads; NK; PBMC; Tumor immunity; Vaccines

Indexed keywords

CD3 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; ARTICLE; CELL CONTACT; CELL SELECTION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOFLUOROMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MONONUCLEAR CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0038667616     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-8749(03)00060-1     Document Type: Article

References (28)

1. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:1998;111-135.
2. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:1998;474-478.
3. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:1998;478-480.
4. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:1998;480-483.
5. Mackey M.F., Gunn J.R., Ting P.P., Kikutani H., Dranoff G., Noelle R.J., Earth R.J. Jr. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 57:1997;2569-2574.
6. Dilloo D., Brown M., Roskrow M., Zhong W., Holladay M., Holden W., Brenner M. CD40 ligand induces an antileukemia immune response in vivo. Blood. 90:1997;1927-1933.
7. Grossmann M.E., Brown M.P., Brenner M.K. Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene. Ther. 8:1997;1935-1943.
8. Nakajima A., Kodama T., Morimoto S., Azuma M., Takeda K., Oshima H., Yoshino S., Yagita H., Okumura K. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161:1998;1901-1907.
9. Gurunathan S., Irvine K.R., Wu C.Y., Cohen J.I., Thomas E., Prussin C., Restifo N.P., Seder R.A. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161:1998;4563-4571.
10. French R.R., Chan H.T., Tutt A.L., Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5:1999;548-553.
11. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:1999;774-779.
12. Sotomayor E.M., Borrello I., Tubb E., Rattis F.M., Bien H., Lu Z., Fein S., Schoenberger S., Levitsky H.I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5:1999;780-787.
13. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D.E., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:2002;423-435.
14. van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., Melief C.J., Toes R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA. 99:2002;5561-5566.
15. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:1999;189-220.
16. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:2001;165-168.
17. Gruber T.A., Skelton D.C., Kohn D.B. Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells. J. Immunol. 168:2002;73-80.
18. Turner J.G., Rakhmilevich A.L., Burdelya L., Neal Z., Imboden M., Sondel P.M., Yu H. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 166:2001;89-94.
19. De Berardinis P., Sartorius R., Fanutti C., Perham R.N., Del Pozzo G., Guardiola J. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat. Biotechnol. 18:2000;873-876.
20. Wu C.Y., Warrier R.R., Carvajal D.M., Chua A.O., Minetti L.J., Chizzonite R., Mongini P.K., Stern A.S., Gubler U., Presky D.H., Gately M.K. Biological function and distribution of human interleukin-12 receptor β chain. Eur. J. Immunol. 26:1996;345-350.
21. Velotti F., Palmieri G., Morrone S., Piccoli M., Frati L., Santoni A. Granzyme A expression by normal rat natural killer (NK) cells in vivo and by interleukin 2-activated NK cells in vitro. Eur. J. Immunol. 19:1989;575-578.
22. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:1996;747-752.
23. Kuniyoshi J.S., Kuniyoshi C.J., Lim A.M., Wang F.Y., Bade E.R., Lau R., Thomas E.K., Weber J.S. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell. Immunol. 193:1999;48-58.
24. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:1995;251-276.
25. Liu C.C., Perussia B., Young J.D. The emerging role of IL-15 in NK-cell development. Immunol. Today. 21:2000;113-116.
26. Carbone E., Ruggiero G., Terrazzano G., Palomba C., Manzo C., Fontana S., Spits H., Karre K., Zappacosta S. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J. Exp. Med. 185:1997;2053-2060.
27. Martin-Fontecha A., Assarsson E., Carbone E., Karre K., Ljunggren H.G. Triggering of murine NK cells by CD40 and CD86 (B7-2). J. Immunol. 162:1999;5910-5912.
28. Terrazzano G., Zanzi D., Palomba C.et al. Differential involvement of CD40, CD80 and major histocompatibility complex class I molecules in cytotoxicity induction and interferon-γ production by human natural killer effectors. J. Leukoc. Biol. 72:2002;305-311.